SynthesisFrontiers in oncology2026
Mapping research trends in macrophage polarization and immunotherapeutic potential in prostate cancer: a bibliometric and visual analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Macrophage polarization plays a critical role in shaping the immunosuppressive tumor microenvironment (TME) of prostate cancer (PCa). Tumor-associated macrophages (TAMs), particularly those exhibiting immunoregulatory and tumor-promoting transcriptional programs, contribute to disease progression, immune evasion, and therapeutic resistance. Objective: To comprehensively map the research landscape of macrophage polarization and activation in PCa using bibliometric tools and to assess translational progress through a review of clinical trials. Methods: A bibliometric analysis was conducted using VOSviewer, CiteSpace, and R, based on publications related to macrophage polarization and activation in PCa. Additionally, eligible interventional clinical trials in prostate cancer were identified through predefined searches of ClinicalTrials.gov and PubMed, and 20 trials were included in the descriptive synthesis. Results: Bibliometric findings revealed growing research interest in macrophage polarization since 2015, with key themes including immune suppression, cytokine signaling, and therapeutic resistance. High-frequency keywords highlighted macrophage plasticity/heterogeneity (often captured by M1/M2-related terms in the literature), immune checkpoints, and TME reprogramming. Clinical trials investigated a range of strategies, including CSF1R inhibition (e.g., cabiralizumab, PLX3397), TAM reprogramming strategies, checkpoint blockade, and combination therapies with PARP inhibitors, radiotherapy, and vaccines. Conclusion: The integration of bibliometric insights with clinical trial and published data highlights the increasing translational focus on TAM/TME-targeted therapies in PCa. These findings underscore macrophage polarization as a promising immunotherapeutic axis and emphasize the need for further clinical innovation and biomarker-driven strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.